Showing 3941-3950 of 10624 results for "".
Understanding Adolescent College Application Stress
https://reachmd.com/programs/clinicians-roundtable/understanding-adolescent-college-application-stress/3067/Understanding the unique stressors of growing up in today’s world is an important part of treating children and adolescents. One of the most challenging events that our children endure is the college application process. Competition for spots at top colleges is at an all-time high. How does this affCommunity-Acquired Pneumonia: Is The First Antibiotic Dose a Good Quality of Care Measure?
https://reachmd.com/programs/clinicians-roundtable/community-acquired-pneumonia-is-the-first-antibiotic-dose-a-good-quality-of-care-measure/3065/The time to first antibiotic dose in patients with community-acquired pneumonia is a core quality measure by which hospitals and physicians are evaluated. Might this time pressure have a negative effect on the accuracy of diagnosis of pneumonia? Dr. James Welker, the Director of the Franklin SquareNeurochemicals and Weight Regulation
https://reachmd.com/programs/clinicians-roundtable/neurochemicals-and-weight-regulation/3023/With a myriad of overlapping hormones and neurotransmitters involved, weight regulation is a complex task. While our bodies aim to stow away energy reserves for emergent times, our patients simultaneously try desperately to shed unwanted pounds. As Sandra Aamodt, PhD, author and former editor-in-chiThe Profile of a Physician in Medical Communications
https://reachmd.com/programs/conference-coverage/the-profile-of-a-physician-in-medical-communications/2924/Long before he went to medical school, Dr. Scott Nelson started out as a disc jockey. Now the 2007-08 president of the National Association of Medical Communicators, Dr. Nelson likes to say, ‘the broadcast bug never went away.’ Dr. Nelson shares his journey through medicine and broadcasting with hosCVD Risk Factors and Cognitive Impairment
https://reachmd.com/programs/lipid-luminations/cvd-risk-factors-and-cognitive-impairment/2803/Dr. Larry Kaskel welcomes Dr. David T. Nash to Lipid Luminations. Dr. Nash is with Syracuse Preventive Cardiology and will discuss how lipid abnormalities and genetic markers are associated with an increased risk for cardiovascular disease and cognitive impairment. He will also speak about how patieState of The Art Treatment for Hepatitis C
https://reachmd.com/programs/clinicians-roundtable/state-of-the-art-treatment-for-hepatitis-c/1946/Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectableDiabetes Nutrition
https://reachmd.com/programs/clinicians-roundtable/diabetes-nutrition/1918/As the epidemic of obesity continues to grow, we can expect that the prevalence of diabetes will rise accordingly. The age distribution of type 2 diabetes is moving younger and younger. What can we do to stop these alarming trends? certified diabetes educator Jeannee Diaz discusses diabetes nutritiProgesterone Primer for Treatment of Brain Inury
https://reachmd.com/programs/clinicians-roundtable/progesterone-primer-for-treatment-of-brain-inury/1789/More than 5 million people in the US are disabled because of brain injury. Dr. Gregory O’Shanick, the national medical director of the Brain Injury Association of America, calls the work of our guest today, “The most promising breakthrough in improving outcomes for TBI”. What is this astonishing brOverview of Movement Disorders
https://reachmd.com/programs/clinicians-roundtable/overview-of-movement-disorder/1644/More than 40 million people are living with a movement disorder, chronic, often painful and debilitating conditions that negatively impact a person's quality of life. These neurological conditions include Parkinson's disease, tics and Tourette's syndrome, tremor, dystonia, spasticity and ataxia amonCK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
https://reachmd.com/programs/neurofrontiers/ck1-inhibition-and-riluzole-in-als-synergy-at-lower-doses/54638/